Short Pulse Width Versus Low Frequency DBS in Parkinson's Disease

NCT ID: NCT05034510

Last Updated: 2023-02-01

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-20

Study Completion Date

2024-03-20

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim is to compare the effect of reducing the conventional pulse width or frequency of stimulation for axial symptoms occurring after Subthalamic nucleus Deep Brain Stimulation (STN DBS) treatment. The participants will be assessed with chronic stimulation with conventional stimulation parameters, namely 60 us and 130 Hz, and after random allocation to short pulse width (30 us) or low frequency (80 Hz).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

STN-DBS implanted patient frequently develop axial symptoms, such as gait and speech disorders, after this surgical procedure, which dampens long-term quality of life of Parkinson's disease patients. The pathogenesis is not completely understood, as it could be either due to a long-term stimulation side effect or a symptom with later onset in disease progression which is not well controlled with actual stimulation program. In case of freezing of gait onset in STN-DBS, literature suggest reducing stimulation frequency. Although, low pulse width is a promising option to tackle speech disorders after STN implant, it is not known its potential therapeutic potential on freezing of gait.

The aim of this investigation is to compare the effect of low frequency and short pulse width stimulation in patients, who develop axial symptoms during long-term follow-up in chronic conventional STN DBS.

As per protocol, participants will be assessed at baseline with chronic standard stimulation parameters (60 us and 130 Hz) then they will be randomly allocated either to a low-frequency (80Hz) or a low-pulse arm (30 us). The study is designed such that after scheduled re-assessment the participant will be switched from low frequency arm to short pulse width and vice versa according to the crossover nature of protocol design. Both the rating investigator and the participant are blinded to the allocation, whereas an unblinded investigator will modify the parameters according to allocation arm.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Parkinson's Disease

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

TRIPLE

Participants Caregivers Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Low frequency 80 Hz then short pulse width 30 usec stimulation

Each participant will undergo to low frequency stimulation for 4 weeks, then will switch to short pulse width stimulation paradigm for 4 weeks according to the crossover design.

Group Type ACTIVE_COMPARATOR

Deep Brain Stimulation

Intervention Type DEVICE

modification in stimulation parameters

Short pulse width 30 usec then low frequency 80 Hz stimulation

Each participant will undergo to short pulse width stimulation paradigm for 4 weeks, then will switch to low frequency for 4 weeks according to the crossover design.

Group Type ACTIVE_COMPARATOR

Deep Brain Stimulation

Intervention Type DEVICE

modification in stimulation parameters

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Deep Brain Stimulation

modification in stimulation parameters

Intervention Type DEVICE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clinical diagnosis of Parkinson's disease
* Subthalamic Nucleus Deep Brain Stimulation with chronic conventional stimulation at 60 usec and 130 Hz for at least 3 months
* Movement Disorder Society UPDRS part III 3.11 \>1
* Freezing of Gait Questionnaire item-3 \>1
* Movement Disorder Society UPDRS part III 3.1 \>1
* Montreal Cognitive Assessment \> 26
* No psychiatric disorders
* All patients will be ≥ 18 years of age
* Documented informed consent

Exclusion Criteria

* no documented informed consent
* axial disorders not related to Parkinson's disease
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

University Hospital of Ferrara

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mariachiara Sensi, PhD

Role: PRINCIPAL_INVESTIGATOR

Azienda Ospedaliero Universitaria di Ferrara

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

University Hospital of Ferrara - Arcispedale Sant'Anna

Ferrara, Emilia-Romagna, Italy

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Italy

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Mariachiara Sensi, PhD

Role: CONTACT

0039-0532-237540

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Mariachiara Sensi, PhD

Role: primary

0039-0532-237540

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

203/2019/Disp/AOUFe

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Deep Brain Stimulation and Parkinson's Disease
NCT02795663 COMPLETED EARLY_PHASE1